Page last updated: 2024-09-04

tipifarnib and Fatigue

tipifarnib has been researched along with Fatigue in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D1
Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J1
Abbruzzese, JL; Giguere, JK; Iqbal, S; Macdonald, JS; McCoy, S; Wade, JL; Whitehead, RP1
Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J1
Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ1
Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ1

Trials

6 trial(s) available for tipifarnib and Fatigue

ArticleYear
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
    Blood, 2003, Mar-01, Volume: 101, Issue:5

    Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome

2005
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
    Investigational new drugs, 2005, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Proto-Oncogene Mas; Quinolones; Survival Rate; Treatment Outcome

2005
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting

2000
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting

2001
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11

    Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting

2002